In the Japanese phase II trial LURET, 1536 patients with EGFR mutation-negative NSCLC were screened, of whom 34 were RET fusion + (2%) and 19 were previously treated patients (10 KIF5B-RET and 6 CCDC6-RET) who were enrolled and treated with vandetanib (300 mg daily), observing an ORR of 53% (9/17), a mDoR of 5.6 months, and a mPFS of 4.7 months. Here, RET is linked to non-small cell lung carcinoma.